Vesugen: The Vascular Endothelium Bioregulator Tripeptide

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Vesugen?

Vesugen is a synthetic tripeptide with the amino acid sequence Lys-Glu-Asp (lysine-glutamic acid-aspartic acid). It is a member of the Khavinson bioregulator peptide family, designed to target vascular endothelial tissue. The name derives from the Latin "vas" (vessel), reflecting its intended specificity for blood vessel biology. Like other bioregulators in this series, Vesugen was developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson.

The vascular endothelium — the single-cell layer lining all blood vessels — plays critical roles in vascular tone regulation, coagulation balance, inflammatory modulation, and angiogenesis. Age-related endothelial dysfunction is recognized as a key contributor to cardiovascular disease, and maintaining endothelial health is a significant area of medical research. For an overview of the entire bioregulator class, see our guide to bioregulator peptides.

Mechanism of Action

Vesugen is proposed to operate through the same epigenetic mechanism attributed to other Khavinson bioregulators. The tripeptide is hypothesized to cross cell membranes, enter the nucleus, and interact with DNA and/or histone proteins in a sequence-specific manner to modulate gene transcription in endothelial cells.

Proposed Targets

• eNOS expression: Published studies suggest that Vesugen may upregulate endothelial nitric oxide synthase (eNOS) gene expression, potentially enhancing nitric oxide production — a key molecule for vasodilation, anti-thrombotic protection, and anti-inflammatory signaling.
• Adhesion molecule regulation: Some reports indicate modulation of endothelial adhesion molecule expression (ICAM-1, VCAM-1), which could influence leukocyte recruitment and inflammatory processes at the vascular wall.
• Endothelial proliferation: Cell culture studies have reported enhanced endothelial cell proliferation and migration with Vesugen treatment, suggesting potential effects on vascular repair and angiogenesis.

Research Findings

In Vitro Studies

Published cell culture experiments from the Khavinson group report that Vesugen treatment of human umbilical vein endothelial cells (HUVECs) enhances proliferation rates, increases eNOS protein expression, and modulates the expression of genes involved in vascular homeostasis. Some studies have used confocal microscopy with fluorescent-labeled peptides to demonstrate nuclear localization of the tripeptide, supporting the proposed mechanism of direct nuclear activity.

Animal Studies

Preclinical studies in aged rats have reported that Vesugen administration improved endothelium-dependent vasodilation, reduced markers of endothelial dysfunction, and partially restored vascular reactivity toward levels observed in younger animals. Some studies combined Vesugen with other bioregulators (such as Cardiogen) and reported synergistic cardiovascular effects.

Critical Assessment

The same methodological limitations that apply to the Khavinson bioregulator series broadly apply to Vesugen specifically. The evidence base consists primarily of publications from affiliated Russian laboratories, with limited independent validation. The proposed mechanism of a tripeptide directly modulating gene expression through DNA interaction remains controversial and unconfirmed by independent structural biology research. No randomized controlled clinical trials have been published.

Safety and Tolerability

As a simple tripeptide composed of common dietary amino acids, Vesugen is expected to have low intrinsic toxicity and rapid metabolic degradation. Published studies report no significant adverse effects in animal models. However, formal toxicology studies meeting international regulatory standards (GLP-compliant studies) have not been published or made publicly available. The safety profile cannot be considered established by Western pharmaceutical standards.

Regulatory Status

Vesugen is not approved by the FDA, EMA, or any major Western regulatory agency. It has been marketed in Russia and some Eastern European countries as a dietary supplement. As with all Khavinson bioregulators, regulatory status varies by jurisdiction, and the compound has not undergone the clinical trial process required for pharmaceutical approval in the United States or European Union.